Cytokinetics appoints Robert E. Landry to board and Audit Committee
Cytokinetics' Board appointed Robert E. Landry as a director on February 10, 2025, filling a vacant seat as a Class II member with a term expiring at the 2027 annual meeting, and also named him to the Audit Committee. The Board determined he is independent, and the filing describes his director pay, including a $440,000 annual equity grant and a one-time option grant with a $700,000 fair value.
Key points
- Robert E. Landry appointed to fill a vacant Board seat effective February 10, 2025; term expires at the 2027 annual meeting.
- Named to the Board's Audit Committee; annual retainer of $12,500 for that role plus a $50,000 Board retainer.
- Annual equity grant with a $440,000 grant date fair value; one-time Initial Grant option with a $700,000 grant date fair value vesting over three years.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.